Your browser doesn't support javascript.
loading
A traveling SARS-CoV-2 laboratory as part of a pandemic response among vulnerable Brazilian populations.
Elias, Maria Carolina; Slavov, Svetoslav Nanev; Lima, Alex Ranieri Jeronimo; Martins, Antonio Jorge; Barros, Claudia Renata Dos Santos; Moretti, Debora Botequio; Araujo, Eduardo L; Marqueze, Elaine Cristina; Ribeiro, Gabriela; Ribeiro, Gabriela Mauric Frossard; Bernardino, Jardelina Souza Todao; Koser, Jaqueline Reginato; Clemente, Luan Gaspar; Crispin, Luiz Aurelio Campos; Alcantara, Luiz Carlos Junior; Coutinho, Luiz Lehmann; Giovanetti, Marta; Silva, Quetura Oliveira; Neto, Raul Machado; Haddad, Ricardo; Kashima, Simone; Viala, Vincent Louis; Covas, Dimas Tadeu; Sampaio, Sandra Coccuzzo.
Affiliation
  • Elias MC; Instituto Butantan, São Paulo, Brazil. carolina.eliassabbaga@butantan.gov.br.
  • Slavov SN; Center of Toxins, Immune Response and Cell Signaling - CeTICSInstituto Butantan, São Paulo, 05503-900, Brazil. carolina.eliassabbaga@butantan.gov.br.
  • Lima ARJ; University of São Paulo, Ribeirão Preto Medical School, Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.
  • Martins AJ; Instituto Butantan, São Paulo, Brazil.
  • Barros CRDS; Instituto Butantan, São Paulo, Brazil.
  • Moretti DB; Instituto Butantan, São Paulo, Brazil.
  • Araujo EL; Instituto Butantan, São Paulo, Brazil.
  • Marqueze EC; Loccus, São Paulo, Brazil.
  • Ribeiro G; Instituto Butantan, São Paulo, Brazil.
  • Ribeiro GMF; Instituto Butantan, São Paulo, Brazil.
  • Bernardino JST; Instituto Butantan, São Paulo, Brazil.
  • Koser JR; Instituto Butantan, São Paulo, Brazil.
  • Clemente LG; Instituto Butantan, São Paulo, Brazil.
  • Crispin LAC; Centro de Genomica Funcional, ESALQ-USP, Piracicaba, São Paulo, Brasil.
  • Alcantara LCJ; Instituto Butantan, São Paulo, Brazil.
  • Coutinho LL; Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
  • Giovanetti M; Centro de Genomica Funcional, ESALQ-USP, Piracicaba, São Paulo, Brasil.
  • Silva QO; Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
  • Neto RM; Instituto Butantan, São Paulo, Brazil.
  • Haddad R; Instituto Butantan, São Paulo, Brazil.
  • Kashima S; Instituto Butantan, São Paulo, Brazil.
  • Viala VL; University of São Paulo, Ribeirão Preto Medical School, Blood Center of Ribeirão Preto, Ribeirão Preto, Brazil.
  • Covas DT; Instituto Butantan, São Paulo, Brazil.
  • Sampaio SC; Instituto Butantan, São Paulo, Brazil.
BMC Public Health ; 23(1): 15, 2023 01 03.
Article in En | MEDLINE | ID: mdl-36597102
BACKGROUND: Brazil has been dramatically hit by the SARS-CoV-2 pandemic and is a world leader in COVID-19 morbidity and mortality. Additionally, the largest country of Latin America has been a continuous source of SARS-CoV-2 variants and shows extraordinary variability of the pandemic strains probably related to the country´s outstanding position as a Latin American economical and transportation hub. Not all regions of the country show sufficient infrastructure for SARS-CoV-2 diagnosis and genotyping which can negatively impact the pandemic response. METHODS: Due to this reason and to disburden the diagnostic system of the inner São Paulo State, the Butantan Institute established the Mobile Laboratory (in Portuguese: LabMovel) for SARS-CoV-2 testing which started a trip of the most important "hotspots" of the most populous Brazilian region. The LabMovel initiated in two important cities of the State: Aparecida do Norte (an important religious center) and the Baixada Santista region which incorporates the port of Santos, the busiest in Latin America. The LabMovel was fully equipped with an automatized system for SARS-CoV-2 diagnosis and sequencing/genotyping. It also integrated the laboratory systems for patient records and results divulgation including in the Federal Brazilian Healthcare System. RESULTS: Currently,16,678 samples were tested, among them 1,217 from Aparecida and 4,564 from Baixada Santista. We tracked the delta introductio in the tested regions with its high diversification. The established mobile SARS-CoV-2 laboratory had a major impact on the Public Health System of the included cities including timely delivery of the results to the healthcare agents and the Federal Healthcare system, evaluation of the vaccination status of the positive individuals in the background of exponential vaccination process in Brazil and scientific and technological divulgation of the fieldwork to the most vulnerable populations. CONCLUSIONS: The SARS-CoV-2 pandemic has demonstrated worldwide the importance of science to fight against this viral agent and the LabMovel shows that it is possible to integrate researchers, clinicians, healthcare workers and patients to take rapid actions that can in fact mitigate this and other epidemiological situations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic_studies Limits: Humans Country/Region as subject: America do sul / Brasil Language: En Journal: BMC Public Health Journal subject: SAUDE PUBLICA Year: 2023 Document type: Article Affiliation country: Brazil Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic_studies Limits: Humans Country/Region as subject: America do sul / Brasil Language: En Journal: BMC Public Health Journal subject: SAUDE PUBLICA Year: 2023 Document type: Article Affiliation country: Brazil Country of publication: United kingdom